Literature DB >> 33633588

The Physiological Mechanisms of the Sex-Based Difference in Outcomes of COVID19 Infection.

Susan Wray1, Sarah Arrowsmith1.   

Abstract

The scale of the SARS-CoV-2 pandemic has thrust a spotlight on the sex-based differences in response to viral diseases; morbidity and mortality are greater in men than women. We outline the mechanisms by which being female offers a degree of protection from COVID19, that persists even when confounders such as comorbidities are considered. The physiological and immunological mechanisms are fascinating and range from incomplete X chromosome inactivation of immune genes, a crucial role for angiotensin converting enzyme 2 (ACE2), and regulation of both immune activity and ACE2 by sex steroids. From this flows understanding of why lung and other organs are more susceptible to COVID19 damage in men, and how their distinct immunological landscapes need to be acknowledged to guide prognosis and treatment. Pregnancy, menopause, and hormone replacement therapy bring changed hormonal environments and the need for better stratification in COVID19 studies. We end by noting clinical trials based on increasing estrogens or progesterone or anti-testosterone drugs; excellent examples of translational physiology.
Copyright © 2021 Wray and Arrowsmith.

Entities:  

Keywords:  ACE2; SARS-CoV-2; hormones; pregnancy; sexual dimorphism; steroid hormones

Year:  2021        PMID: 33633588      PMCID: PMC7900431          DOI: 10.3389/fphys.2021.627260

Source DB:  PubMed          Journal:  Front Physiol        ISSN: 1664-042X            Impact factor:   4.566


  88 in total

1.  Regulatory effects of estrogen on acute lung inflammation in mice.

Authors:  Cecilia L Speyer; Nicholas J Rancilio; Shannon D McClintock; Jeffrey D Crawford; Hongwei Gao; J Vidya Sarma; Peter A Ward
Journal:  Am J Physiol Cell Physiol       Date:  2005-04       Impact factor: 4.249

2.  Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia.

Authors:  Axel M Hillmer; Sandra Hanneken; Sibylle Ritzmann; Tim Becker; Jan Freudenberg; Felix F Brockschmidt; Antonia Flaquer; Yun Freudenberg-Hua; Rami Abou Jamra; Christine Metzen; Uwe Heyn; Nadine Schweiger; Regina C Betz; Bettina Blaumeiser; Jochen Hampe; Stefan Schreiber; Thomas G Schulze; Hans Christian Hennies; Johannes Schumacher; Peter Propping; Thomas Ruzicka; Sven Cichon; Thomas F Wienker; Roland Kruse; Markus M Nothen
Journal:  Am J Hum Genet       Date:  2005-05-18       Impact factor: 11.025

3.  TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.

Authors:  Adeline Heurich; Heike Hofmann-Winkler; Stefanie Gierer; Thomas Liepold; Olaf Jahn; Stefan Pöhlmann
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

4.  Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.

Authors:  Harmony R Reynolds; Samrachana Adhikari; Claudia Pulgarin; Andrea B Troxel; Eduardo Iturrate; Stephen B Johnson; Anaïs Hausvater; Jonathan D Newman; Jeffrey S Berger; Sripal Bangalore; Stuart D Katz; Glenn I Fishman; Dennis Kunichoff; Yu Chen; Gbenga Ogedegbe; Judith S Hochman
Journal:  N Engl J Med       Date:  2020-05-01       Impact factor: 91.245

Review 5.  Sex differences in severity and mortality from COVID-19: are males more vulnerable?

Authors:  Ajay Pradhan; Per-Erik Olsson
Journal:  Biol Sex Differ       Date:  2020-09-18       Impact factor: 5.027

6.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.

Authors:  I Hamming; W Timens; M L C Bulthuis; A T Lely; G J Navis; H van Goor
Journal:  J Pathol       Date:  2004-06       Impact factor: 7.996

7.  Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.

Authors:  Masato Furuhashi; Norihito Moniwa; Hideki Takizawa; Nobuyuki Ura; Kazuaki Shimamoto
Journal:  Hypertens Res       Date:  2020-05-20       Impact factor: 3.872

Review 8.  Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes.

Authors:  Franck Mauvais-Jarvis; Sabra L Klein; Ellis R Levin
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

Review 9.  The Meaning of Mas.

Authors:  Michael Bader; Natalia Alenina; Dallan Young; Robson A S Santos; Rhian M Touyz
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

View more
  12 in total

1.  Disparities by Sex in COVID-19 Risk and Related Harms Among People with Opioid Use Disorder.

Authors:  Caitlin E Martin; Bhushan Thakkar; DaShaunda D H Taylor; Derek A Chapman
Journal:  J Womens Health (Larchmt)       Date:  2022-02-15       Impact factor: 3.017

Review 2.  COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes.

Authors:  Banafsheh Bigdelou; Mohammad Reza Sepand; Sahar Najafikhoshnoo; Jorge Alfonso Tavares Negrete; Mohammed Sharaf; Jim Q Ho; Ian Sullivan; Prashant Chauhan; Manina Etter; Tala Shekarian; Olin Liang; Gregor Hutter; Rahim Esfandiarpour; Steven Zanganeh
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

3.  Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study.

Authors:  Coskun Ozer Demirtas; Caglayan Keklikkiran; Ilkay Ergenc; Buket Erturk Sengel; Gunes Eskidemir; Ismail Cinel; Zekaver Odabasi; Volkan Korten; Yusuf Yilmaz
Journal:  Int J Clin Pract       Date:  2021-05-29       Impact factor: 3.149

Review 4.  Polycystic ovary syndrome and risks for COVID-19 infection: A comprehensive review : PCOS and COVID-19 relationship.

Authors:  Sebastião Freitas de Medeiros; Márcia Marly Winck Yamamoto; Matheus Antônio Souto de Medeiros; Ana Karine Lin Winck Yamamoto; Bruna Barcelo Barbosa
Journal:  Rev Endocr Metab Disord       Date:  2022-02-26       Impact factor: 9.306

5.  Predicting respiratory failure in patients infected by SARS-CoV-2 by admission sex-specific biomarkers.

Authors:  Maria Teresa Pagano; Daniela Peruzzu; Luca Busani; Marina Pierdominici; Anna Ruggieri; Andrea Antinori; Gianpiero D'Offizi; Nicola Petrosillo; Fabrizio Palmieri; Pierluca Piselli; Stefania Cicalini; Stefania Notari; Emanuele Nicastri; Chiara Agrati; Giuseppe Ippolito; Francesco Vaia; Maria Cristina Gagliardi; Maria Rosaria Capobianchi; Elena Ortona
Journal:  Biol Sex Differ       Date:  2021-11-22       Impact factor: 5.027

6.  Impact of Age and Sex on COVID-19 Severity Assessed From Radiologic and Clinical Findings.

Authors:  Yauhen Statsenko; Fatmah Al Zahmi; Tetiana Habuza; Taleb M Almansoori; Darya Smetanina; Gillian Lylian Simiyu; Klaus Neidl-Van Gorkom; Milos Ljubisavljevic; Rasha Awawdeh; Hossam Elshekhali; Martin Lee; Nassim Salamin; Ruhina Sajid; Dhanya Kiran; Sanjay Nihalani; Tom Loney; Antony Bedson; Alireza Dehdashtian; Jamal Al Koteesh
Journal:  Front Cell Infect Microbiol       Date:  2022-02-25       Impact factor: 5.293

Review 7.  Estrogen Receptor Modulators in Viral Infections Such as SARS-CoV-2: Therapeutic Consequences.

Authors:  Nikita Abramenko; Fréderic Vellieux; Petra Tesařová; Zdeněk Kejík; Robert Kaplánek; Lukáš Lacina; Barbora Dvořánková; Daniel Rösel; Jan Brábek; Adam Tesař; Milan Jakubek; Karel Smetana
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

Review 8.  Genetic and epigenetic control of ACE2 expression and its possible role in COVID-19.

Authors:  Rafael Silva Lima; Luiz Paulo Carvalho Rocha; Paula Rocha Moreira
Journal:  Cell Biochem Funct       Date:  2021-06-01       Impact factor: 3.963

Review 9.  Basic mechanisms of SARS-CoV-2 infection. What endocrine systems could be implicated?

Authors:  Manel Puig-Domingo; Mónica Marazuela; Berta Soldevila
Journal:  Rev Endocr Metab Disord       Date:  2021-07-31       Impact factor: 9.306

10.  [COVID-19 from the perspective of a gynecological endocrinologist].

Authors:  Ricardo Felberbaum; Wolfgang Küpker
Journal:  Gynakol Endokrinol       Date:  2021-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.